Nasal delivery of PLG microparticle encapsulated defensin peptides adjuvanted gp41 antigen confers strong and long-lasting immunoprotective response against HIV-1.
about
Advanced Nanobiomaterials: Vaccines, Diagnosis and Treatment of Infectious DiseasesIntranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunityCo-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 virusesNovel adjuvants & delivery vehicles for vaccines development: a road aheadAn overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.Towards the Application of Human Defensins as Antivirals.Sequential immunizations with a panel of HIV-1 Env virus-like particles coach immune system to make broadly neutralizing antibodies.
P2860
Q26744748-CB3D5FCF-CA9A-4028-AC52-898D21961258Q33708572-AC2CCD9F-14D6-4435-ACA3-4F46C0D9F464Q37018558-E232DFE7-B601-4E5A-A42B-CE84D14B0FF1Q37592383-345DD1CE-714A-4C55-A3C1-7AE24230BE8BQ39174792-FAA178C4-BF30-4D76-87CF-CE9FBA73830DQ47557198-5E7B72D8-159B-4FC2-9D6C-640A029B6A41Q54207383-41BDB943-BB7B-4E5C-A3EC-0FB8EF891E6B
P2860
Nasal delivery of PLG microparticle encapsulated defensin peptides adjuvanted gp41 antigen confers strong and long-lasting immunoprotective response against HIV-1.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Nasal delivery of PLG micropar ...... ective response against HIV-1.
@en
Nasal delivery of PLG micropar ...... ective response against HIV-1.
@nl
type
label
Nasal delivery of PLG micropar ...... ective response against HIV-1.
@en
Nasal delivery of PLG micropar ...... ective response against HIV-1.
@nl
prefLabel
Nasal delivery of PLG micropar ...... ective response against HIV-1.
@en
Nasal delivery of PLG micropar ...... ective response against HIV-1.
@nl
P2093
P2860
P1433
P1476
Nasal delivery of PLG micropar ...... ective response against HIV-1.
@en
P2093
P2860
P2888
P304
P356
10.1007/S12026-013-8428-5
P577
2014-01-01T00:00:00Z